Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date Sort descending | Purpose |
|---|---|---|---|---|---|
| Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed) | RFA-DK-23-007 | NIDDK | This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may… More | ||
| Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional) | RFA-DA-25-028 | NIDA | The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into… More | ||
| NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) | PAR-21-220 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).… More | ||
| Notice of Special Interest (NOSI): Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21) | NOT-OD-24-026 | OD | The purpose of this Notice of Special Interest (NOSI) is to support secondary data analysis to address questions and advance scientific inquiry related to SARS-CoV-2 through the existing data… More | ||
| Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trials Optional) | RFA-DA-25-043 | NIDA | This notice of funding opportunity (NOFO) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based,… More | ||
| Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional) | RFA-DK-25-010 | NIDDK | This Notice of Funding Opportunity (NOFO) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both… More | ||
| Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial Optional) | RFA-DK-24-002 | NIDDK | The main objective of this NOFO is to foster development and testing of technologies adaptable to aging-related changes in older adults (aged 65 years or older) with T1D to improve diabetes… More | ||
| Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed) | RFA-TR-24-021 | NCATS | This is a non-competitive funding opportunity intended to fund a single award. NCATS is announcing its intent to issue a single source cooperative agreement to Cincinnati Childrens Hospital Medical… More | ||
| Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 - Clinical Trial Not Allowed) | RFA-HD-25-009 | NICHD | The purpose of this Notice of Funding Opportunity (NOFO) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative will… More | ||
| Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed) | RFA-DA-25-053 | NIDA | The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance… More |